hereditary angioedema - Search News

News

Hereditary Angioedema, RNA

The American Journal of Manage… · 3d

FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

Medpage Today on MSN · 2d

RNA-Targeted Drug Approved for Preventing Hereditary Angioedema Attacks

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly subcutaneously. Weeks later, regulators approved sebetralstat (Ekterly) as an oral, on-demand therapy for HAE.

Yahoo Finance · 3d

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

3d

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Fierce Pharma3d

Ionis steps into crowded HAE market with FDA approval for Dawnzera

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

2d

What's Going On With Takeda Stock On Friday?

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results